TNF

THE NEWS FORUM - Broadcast Exclusive - GLOBAL WARNING – Saturday April 20 and Sunday April 21 at 8PM ET

Retrieved on: 
星期四, 四月 18, 2024
The News Forum, Climate change, TNF, Science, Biophysical environment, Politics, Hope, Knowledge, Face, Policy, Entertainment

"Global Warning" delves deep into the nexus of science and politics surrounding the escalating energy demands and the pressing need to safeguard our planet.

Key Points: 
  • "Global Warning" delves deep into the nexus of science and politics surrounding the escalating energy demands and the pressing need to safeguard our planet.
  • Featuring exclusive interviews with eminent scholars and experts, "Global Warning" offers viewers an unprecedented insight into the challenges and opportunities facing humanity in the 21st century.
  • As the world grapples with the existential threat of climate change, "Global Warning" emerges as a beacon of hope and enlightenment.
  • "Global Warning" is slated for broadcast release Saturday April 20 at 8PM ET and will be repeated on Sunday April 21 at 8PM ET.

The News Forum - Exclusive Interview with former Israeli Prime Minister Naftali Bennett with 15-year-old Wyatt Sharpe - TONIGHT on FORUM DAILY NEWS at 6PM.

Retrieved on: 
星期二, 四月 16, 2024
The News Forum, TNF, Heart, Tune, Interview, Human

ST. CATHARINES, Ontario, April 16, 2024 (GLOBE NEWSWIRE) -- The News Forum (TNF) – Former Prime Minister Naftali Bennett is set to engage in an exclusive and groundbreaking interview with 15-year-old Wyatt Sharpe on Forum Daily News, airing tonight at 6 PM.

Key Points: 
  • ST. CATHARINES, Ontario, April 16, 2024 (GLOBE NEWSWIRE) -- The News Forum (TNF) – Former Prime Minister Naftali Bennett is set to engage in an exclusive and groundbreaking interview with 15-year-old Wyatt Sharpe on Forum Daily News, airing tonight at 6 PM.
  • "We are thrilled to have the opportunity to feature this conversation with Wyatt Sharpe on Forum Daily News," said Tore Stautland, CEO of The News Forum.
  • His determination to engage with pressing global issues underscores the importance of youth participation in shaping the world they inherit.
  • Tune in to Forum Daily News tonight at 6 PM to witness this exclusive interview between former Prime Minister Naftali Bennett and Wyatt Sharpe, as they explore the complexities of the Israel-Palestine conflict and Canada’s role in the pursuit of peace.

NIMML Institute Presents Pioneering Research on Immunometabolic Mechanisms Related to the Pharmacological Activation of LANCL Receptors at Immunology2024, the Annual Meeting of the American Association of Immunologists

Retrieved on: 
星期三, 四月 10, 2024
Health Technology, Other Health, Technology, Pharmaceutical, Oncology, Mental Health, Philanthropy, Infectious Diseases, Genetics, Artificial Intelligence, Clinical Trials, Foundation, Biotechnology, Science, Research, Health, Eosinophilia, Bronchial hyperresponsiveness, NIMML, Swelling, Choline, PBMC, Gastrointestinal tract, Macrophage, Fibrosis, Red, Atopic dermatitis, Brain, TNF, Inflammation, Phenotype, Abstract, Glycolysis, Lupus, T helper 17 cell, IBD, AAI, Psoriasis, OVA, MASH, Plasma, Fed, Ulcerative colitis, Mouse, COL1A1, Microglia, McCormick Place, Therapy, Carbon tetrachloride, HDM, Immunoglobulin E, IL-6, Medicine, Asthma, House, Neutrophil, Patient, Phagocytosis, Ovalbumin, Rheumatoid arthritis, LANCL2, CDAA, UC

The AAI meeting will take place at McCormick Place in Chicago, Illinois from May 3 to May 7, 2024.

Key Points: 
  • The AAI meeting will take place at McCormick Place in Chicago, Illinois from May 3 to May 7, 2024.
  • “We are pleased to present our most recent findings related to the immunometabolic mechanisms of activation of LANCL receptors in inflammation & immunology at this year’s AAI Annual Meeting,” said Dr. Josep Bassaganya-Riera, President and Founding Director of NIMML.
  • NImmune’s portfolio includes first and best-in-class omilancor and NIM-1324, two oral, once-daily agonistic therapeutics that bind and activate the LANCL2 pathway.
  • Title: Pharmacological activation of LANCL2 provides immunometabolic support for the restoration of cognitive function markers in a mouse model of Alzheimer’s disease.

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Retrieved on: 
星期五, 四月 19, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Ulcerative colitis, TNF, Azathioprine, CDAI, Safety, Education, Food, MD, Burnett School of Medicine, Week, Patient, Methotrexate, UC, Pharmaceutical industry

“Crohn’s disease is a complex and usually progressive disease for which an appropriate management plan is critical.

Key Points: 
  • “Crohn’s disease is a complex and usually progressive disease for which an appropriate management plan is critical.
  • “Our development of a subcutaneous option demonstrates Takeda’s commitment to meeting the very real needs of those living with gastrointestinal diseases.”
    *Please refer to “U.S.
  • FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis”, dated September 27, 2023.
  • Takeda does not expect a material impact on the consolidated financial statements as a result of this approval.

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

Retrieved on: 
星期一, 四月 8, 2024
TNF, MUC4, Alpha globulin, Disease, Macrophage, CD47, LAG3, Breast cancer, TIGIT, Poster, ADCP, TNBC, Vaccine

Boca Raton, Florida, April 08, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative tumor necrosis factor (TNF) inhibitor of soluble TNF (sTNF) in the treatment of high-risk MUC4 expressing HER2+ and triple negative breast cancer (TNBC).  INB03 is shown to decrease T cell and macrophage immune checkpoint proteins (PD1, TIGIT, LAG3, CD47 and SIRPa) in a model immunotherapy resistant HER2+ breast cancer and decrease the metastatic potential of TNBC by downregulating cell surface markers of tumor invasion (MUC4, SNAIL and Vimectin).  The two posters will be presented at the annual American Association of Cancer Research in San Diego on April 8, 2024.

Key Points: 
  • The two posters will be presented at the annual American Association of Cancer Research in San Diego on April 8, 2024.
  • Decreases in T cell and macrophage immune checkpoint proteins were caused by INB03.
  • The authors speculate that these effects could avoid tumor immune evasion to anti-HER2 targeted therapies by reinvigorating the immune infiltrate.
  • Dr. Schillaci, senior author of the study, proposes INB03 is a new class of immunotherapy called a pan immune checkpoint modulator in MUC4 expressing breast cancer.

Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development

Retrieved on: 
星期四, 四月 4, 2024
Toxicity, TNF, Absorption, Ulcerative colitis, Plasma, Tmax, SAN, Patient, UC, MD, Cmax, IBD, Clinical trial, Therapy, Safety, Pharmacokinetics, SAD, JAK, Pharmaceutical industry

SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today shared additional positive interim results from the single-ascending dose (SAD) clinical trial of BT-600, which is a drug-device combination consisting of the orally administered NaviCap™ device that delivers a proprietary liquid formulation of tofacitinib to the colon. BT-600 is being developed for the potential treatment of patients with ulcerative colitis (UC). The SAD portion of the phase 1 randomized, double-blind, placebo-controlled clinical trial tested the tolerability and pharmacokinetics of BT-600 at 5 mg and 10 mg doses of tofacitinib, compared to placebo, in healthy adult participants.

Key Points: 
  • BT-600 is being developed for the potential treatment of patients with ulcerative colitis (UC).
  • The SAD portion of the phase 1 randomized, double-blind, placebo-controlled clinical trial tested the tolerability and pharmacokinetics of BT-600 at 5 mg and 10 mg doses of tofacitinib, compared to placebo, in healthy adult participants.
  • We believe this could lead to better outcomes for patients suffering from UC.”
    According to the interim clinical data, all pharmacokinetic endpoints were met in all study participants.
  • The mean time to reach maximum concentration (Tmax) was 8–10 hours following administration of BT-600, versus 0.5-1.0 hours for conventional oral tofacitinib.

Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress

Retrieved on: 
星期一, 三月 18, 2024
Research, TNF, AON, Dexamethasone, Congress, International, International Financial Reporting Standards, Telecanthus, Inflammation, DME, Patient, SNP, NDA, American Academy, G&A, POC, Business analyst, IND, Abstract, DED, Bank statement, Genotype, Investment, Retina, Diabetic retinopathy, OCS, Safety, CHF, Pain, Stage 2, Pharmaceutical industry

Riad Sherif M.D., Chief Executive Officer of Oculis: “2023 was a remarkable milestone-rich year for Oculis.

Key Points: 
  • Riad Sherif M.D., Chief Executive Officer of Oculis: “2023 was a remarkable milestone-rich year for Oculis.
  • These non-IFRS financial measures exclude the impact of items that the Company’s management believes affect comparability or underlying business trends.
  • The Company’s management uses these measures to better analyze its financial results and better estimate its financial outlook.
  • The resulting non-cash foreign exchange impact of such reclassification amounted to CHF 5.0 million or $5.7 million for the year ended December 31, 2023.

Global Irritable Bowel Disease (IBD) Market Analysis Report 2024: Increasing Prevalence of Crohn's Disease, and Ulcerative Colitis Driving the $21 Billion Market - Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
星期二, 三月 12, 2024
General Health, Pharmaceutical, Health, Corticosteroid, TNF, Injection (medicine), Growth, Prevalence, Porter's five forces analysis, Incidence, SWOT, Disease, Research, IBD, Market, Medicine, Crohn's disease, Route of administration, Ulcerative colitis, USD, Administration, JAK, Irritable bowel syndrome, Pharmaceutical industry

The Global Irritable Bowel Disease market showcased growth at a CAGR of 2.60% during 2019-2022.

Key Points: 
  • The Global Irritable Bowel Disease market showcased growth at a CAGR of 2.60% during 2019-2022.
  • The increasing incidence and prevalence of Crohn's Disease, and Ulcerative Colitis are major drivers for the growth of the Market.
  • The report analyses the Irritable Bowel Disease Market by Drug Class (Corticosteroids, JAK inhibitors, TNF inhibitors, Other Drug Classes)
    The report analyses the Irritable Bowel Disease Market By Route of Administration (Injectable, Oral).
  • The report analyses the Irritable Bowel Disease Market by Indication (Crohn's Disease, Ulcerative Colitis).

Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics

Retrieved on: 
星期二, 三月 12, 2024
Cream, TNF, EUR, Psoriasis, Agreement, Inflammation, Patient, PAD, Dermatology, MC2, Skin, Gold, Comorbidity, Safety, Good, Pharmaceutical industry

SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.

Key Points: 
  • SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
  • Ltd., has entered into an exclusive license, supply and commercialisation agreement (the "Agreement") with MC2 Therapeutics ("MC2") for the exclusive rights to register and commercialise Wynzora® Cream and all future product extensions and/or improvements for the topical treatment of plaque psoriasis in the 10 ASEAN countries.
  • Wynzora® Cream ( www.wynzora.com ), is a leading topical treatment for plaque psoriasis, including scalp psoriasis in adults.
  • "Hyphens Pharma is a leading specialty pharma company focused on the commercialisation of innovative pharmaceutical products in the ASEAN region.

Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics

Retrieved on: 
星期二, 三月 12, 2024
Cream, TNF, EUR, Psoriasis, Agreement, Inflammation, Patient, PAD, Dermatology, MC2, Skin, Gold, Comorbidity, Safety, Good, Pharmaceutical industry

SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.

Key Points: 
  • SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
  • Ltd., has entered into an exclusive license, supply and commercialisation agreement (the "Agreement") with MC2 Therapeutics ("MC2") for the exclusive rights to register and commercialise Wynzora® Cream and all future product extensions and/or improvements for the topical treatment of plaque psoriasis in the 10 ASEAN countries.
  • Wynzora® Cream ( www.wynzora.com ), is a leading topical treatment for plaque psoriasis, including scalp psoriasis in adults.
  • "Hyphens Pharma is a leading specialty pharma company focused on the commercialisation of innovative pharmaceutical products in the ASEAN region.